How J&J's Spravato launch created the clinic infrastructure Compass needs for its potential COMP360 psychedelic rollout

Compass Pathways executives describe how Johnson & Johnson's launch of the ketamine-based depression treatment Spravato helped build a U.S. network of about 8,500 interventional psychiatry clinics that could support COMP360, Compass's synthetic psilocybin treatment, if the FDA approves it. The company says these centers already have staff, rooms and reimbursement systems for monitored in-office care, although COMP360 would require six to eight hours of observation compared with roughly three hours for Spravato. Compass plans a contained, closely managed launch before scaling, with field teams hired after approval and a commercial organization that has grown from 20 to about 100 people. Executives expect treatment to occur only one to four times per year, potentially easing adherence, and report mostly mild, transient trial side effects. They argue the large unmet need in depression leaves room for multiple psychedelic therapies, while acknowledging that clinicians still cannot predict which patients will respond. The article presents Spravato as an infrastructure and commercialization precedent rather than a direct competitor.